Ratings SenzaGen AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 16:29:45 06/05/2024 BST			5-day change	1st Jan Change
8.74 ^SEK	+9.25%		+36.99%	+20.05%

03-25	Senzagen Receives Follow-Up Order Worth SEK 0.8 Million from the Global Chemicals Leader	CI
03-22	SenzaGen AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SENZAGEN AB	+20.05%	17.91M		-
EXACT SCIENCES CORPORATION	-14.37%	11.41B		A-
IOVANCE BIOTHERAPEUTICS, INC.	+70.73%	3.81B		D+
GUARDANT HEALTH, INC.	-29.39%	2.3B		C
BGI GENOMICS CO., LTD.	-12.90%	2.16B	-	B-
MARAVAI LIFESCIENCES HOLDINGS, INC.	+37.56%	1.19B		B-
SEEGENE, INC.	-2.40%	760M		C+
CAREDX, INC	-15.17%	506M		C-
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-34.29%	444M		C-
CURIOX BIOSYSTEMS CO., LTD	+13.72%	339M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality